HUE058854T2 - Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával - Google Patents

Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Info

Publication number
HUE058854T2
HUE058854T2 HUE19210193A HUE19210193A HUE058854T2 HU E058854 T2 HUE058854 T2 HU E058854T2 HU E19210193 A HUE19210193 A HU E19210193A HU E19210193 A HUE19210193 A HU E19210193A HU E058854 T2 HUE058854 T2 HU E058854T2
Authority
HU
Hungary
Prior art keywords
cancer
antibody
age
composition
end products
Prior art date
Application number
HUE19210193A
Other languages
English (en)
Inventor
Lewis Gruber
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of HUE058854T2 publication Critical patent/HUE058854T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE19210193A 2016-02-19 2017-02-16 Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával HUE058854T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662297744P 2016-02-19 2016-02-19
US201662425495P 2016-11-22 2016-11-22

Publications (1)

Publication Number Publication Date
HUE058854T2 true HUE058854T2 (hu) 2022-09-28

Family

ID=58191665

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17708098A HUE047922T2 (hu) 2016-02-19 2017-02-16 Rák kezelésére, metasztatikus rákos sejtek elpusztítására és rák metasztázisának megelõzésére szolgáló, módszer és készítmény elõrehaladott glikációs végtermékek (AGE) elleni antitestek felhasználásával
HUE19210193A HUE058854T2 (hu) 2016-02-19 2017-02-16 Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17708098A HUE047922T2 (hu) 2016-02-19 2017-02-16 Rák kezelésére, metasztatikus rákos sejtek elpusztítására és rák metasztázisának megelõzésére szolgáló, módszer és készítmény elõrehaladott glikációs végtermékek (AGE) elleni antitestek felhasználásával

Country Status (17)

Country Link
US (1) US11833202B2 (hu)
EP (3) EP4067386A1 (hu)
JP (2) JP6722293B2 (hu)
KR (2) KR20230074837A (hu)
CN (1) CN109071675A (hu)
AU (1) AU2017219749B2 (hu)
CA (1) CA3021150C (hu)
DK (2) DK3677598T3 (hu)
ES (2) ES2912064T3 (hu)
HK (1) HK1256931A1 (hu)
HU (2) HUE047922T2 (hu)
IL (2) IL261006B (hu)
MX (2) MX2018009988A (hu)
PL (1) PL3337829T3 (hu)
PT (1) PT3337829T (hu)
RU (1) RU2728964C2 (hu)
WO (1) WO2017143073A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640249C2 (ru) 2008-05-23 2017-12-27 Сива Корпорейшн Способы, композиции и приборы для облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
KR102438295B1 (ko) 2014-09-19 2022-08-31 시와 코퍼레이션 염증 및 자가 면역 질환을 치료하기 위한 노화 방지 항체
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
KR20200003067A (ko) 2017-05-04 2020-01-08 시와 코퍼레이션 진단용 최종 당화 산물 항체
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020023532A1 (en) * 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
EP3840840A1 (en) 2018-08-23 2021-06-30 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
AU2021264007A1 (en) 2020-05-01 2022-12-08 Siwa Corporation Methods of treating infections
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4900747A (en) 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5811075A (en) 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
AU600306B2 (en) 1986-09-12 1990-08-09 Rockefeller University, The Methods and agents for removing advanced glycosylation endproducts
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040208826A1 (en) 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20080063603A1 (en) 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (hu) 1990-04-02 1993-05-01 Sint Sa
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
CA2126080A1 (en) 1991-12-20 1993-07-08 Jean-Yves Chapelon Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
WO1994000592A1 (en) 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en) 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5518720A (en) 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5744300A (en) 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
CA2208411A1 (en) 1994-12-30 1996-07-11 Alteon, Inc. Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
US5744318A (en) 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
AU6907496A (en) 1995-08-25 1997-03-19 Case Western Reserve University Process for detecting pentosidine and for assessing the biological age of a biological sample
US5620409A (en) 1995-09-15 1997-04-15 The Research Foundation Of State University Of New York Method for inhibiting clot formation
JP3579549B2 (ja) 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5664570A (en) 1996-02-20 1997-09-09 Svc Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
WO1999007893A1 (en) 1997-08-08 1999-02-18 University Of Washington ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6896659B2 (en) 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
JP4016304B2 (ja) 1998-02-26 2007-12-05 日本油脂株式会社 モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法
WO1999064463A1 (en) 1998-06-09 1999-12-16 Alteon Inc. Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
JP2002526117A (ja) 1998-10-06 2002-08-20 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 細胞外新規ｒａｇｅ結合タンパク質（ｅｎ−ｒａｇｅ）及びその使用
US6309355B1 (en) 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
EP1159003B1 (en) 1999-03-02 2010-11-17 Centocor, Inc. Anti-tnf alpha antibodies in therapy of steroid resistant asthma
US6067859A (en) 1999-03-04 2000-05-30 The Board Of Regents, The University Of Texas System Optical stretcher
ATE437655T1 (de) 1999-06-25 2009-08-15 Genentech Inc Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
JP2003507013A (ja) 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US6853864B2 (en) 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001089584A2 (en) 2000-05-23 2001-11-29 Amersham Health As Contrast agents
NO312338B1 (no) 2000-08-25 2002-04-29 Gunnar Myhr Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN2445326Y (zh) 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
US7481781B2 (en) 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
DE60134177D1 (de) 2001-01-03 2008-07-03 Ultrashape Inc Eingriffsfreie ultraschall körperkonturierung
ATE283481T1 (de) 2001-03-22 2004-12-15 Hoffmann La Roche Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten
EP1415997A4 (en) 2001-07-19 2005-03-30 Mitsubishi Pharma Corp POLYPEPTIDES RELATING TO TRANSFER OF RECEPTOR SIGNALS FROM ADVANCED GLYCATION TERMINAL PRODUCTS
JP4012722B2 (ja) 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
ATE547416T1 (de) 2002-07-24 2012-03-15 Dermira Canada Inc Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
AU2003265505A1 (en) 2002-08-16 2004-03-03 Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
US20070128117A1 (en) 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1601969A2 (en) 2003-03-08 2005-12-07 Auvation Ltd Markers for colorectal cancer
JP2007500521A (ja) 2003-07-31 2007-01-18 ウッドウェルディング・アクチェンゲゼルシャフト 傷口面に組織再生を促進する方法と装置
US7358226B2 (en) 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
WO2005070472A2 (en) 2004-01-20 2005-08-04 Sunnybrook And Women's College Health Sciences Centre, High frequency ultrasound imaging using contrast agents
CA2557837A1 (en) 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
AP2007003869A0 (en) 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1866663A1 (en) 2005-03-03 2007-12-19 Bracco Research S.A. Medical imaging system based on a targeted contrast agent
JP2006249015A (ja) 2005-03-11 2006-09-21 Mochida Pharmaceut Co Ltd 細胞老化抑制剤
CN101120019A (zh) 2005-04-05 2008-02-06 株式会社Jms 对3,4-DGE来源的AGEs特异性反应的抗体
JP2006288864A (ja) 2005-04-13 2006-10-26 Padoru:Kk 外科手術用の骨固定具
US20070225242A1 (en) 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070059247A1 (en) 2005-08-30 2007-03-15 Lindner Jonathan R Deposit contrast agents and related methods thereof
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en) 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US20070078290A1 (en) 2005-09-30 2007-04-05 Esenaliev Rinat O Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
US7766833B2 (en) 2005-11-23 2010-08-03 General Electric Company Ablation array having independently activated ablation elements
JP4779115B2 (ja) * 2005-12-16 2011-09-28 国立大学法人東北大学 早期肺癌の術後予後検査方法
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
WO2008154638A2 (en) * 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
CA2690056C (en) 2007-06-14 2017-08-29 Galactica Pharmaceuticals, Inc. Rage fusion proteins
JP2007277263A (ja) 2007-07-13 2007-10-25 Transgenic Inc カルボキシメチル化タンパク質に対する抗体
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
DE102008009461A1 (de) 2008-02-15 2009-08-20 Beiersdorf Ag Verfahren zur Reduzierung der Zeichen der Hautalterung
AU2009245354C1 (en) 2008-05-09 2016-05-19 AbbVie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
RU2640249C2 (ru) 2008-05-23 2017-12-27 Сива Корпорейшн Способы, композиции и приборы для облегчения регенерации
JP5229473B2 (ja) 2008-06-04 2013-07-03 財団法人ヒューマンサイエンス振興財団 超音波医療装置
WO2010005531A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
EP2399934B1 (en) 2009-02-20 2017-09-06 The University of Tokyo Novel monoclonal antibody, and use thereof
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011035104A1 (en) 2009-09-17 2011-03-24 Sanuwave, Inc. Methods and devices for cleaning and sterilization with shock waves
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
EP2493486A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en) 2010-02-22 2011-08-25 Universite Pierre Et Marie Curie (Paris 6) Apparatus for the treatment of brain affections and method implementing thereof
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2013009787A2 (en) 2011-07-10 2013-01-17 Guided Therapy Systems, Llc Methods and systems for ultrasound treatment
US8954155B2 (en) 2011-09-19 2015-02-10 Biotalk Technologies Inc Apparatus and method for rejuvenating skin
EP2758431A1 (en) 2011-09-23 2014-07-30 Julius-Maximilians-Universität Würzburg Peptide or arrangement of peptides forming a staphylococcus aureus epitope binding site
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
BR112014014529A2 (pt) 2011-12-13 2019-09-24 Buck Inst For Res On Aging métodos para melhorar terapias médicas
EA031069B1 (ru) 2012-02-17 2018-11-30 Сиэтл Дженетикс, Инк. АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
KR101520336B1 (ko) 2012-11-30 2015-05-14 전남대학교산학협력단 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
EP2742935A1 (en) 2012-12-14 2014-06-18 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH SERF2 for the treatment of atrophy and for increasing cell growth
BR112015021708A2 (pt) 2013-03-06 2017-08-29 Protalix Ltd Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa
US20140257262A1 (en) 2013-03-11 2014-09-11 Alexandre Carpentier Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
ES2808726T3 (es) 2013-03-12 2021-03-01 Molecular Templates Inc Inmunotoxinas de unión a CD20 para inducir la internalización celular y procedimientos que usan las mismas
JP6549560B2 (ja) 2013-05-14 2019-07-24 上海 ハイチャーム インコーポレーテッドＳｈａｎｇｈａｉ Ｈｙｃｈａｒｍ Ｉｎｃ． 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用
CN107106700B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3094350B1 (en) 2014-01-15 2020-03-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cartilage targeting agents and their use
WO2015112835A1 (en) 2014-01-24 2015-07-30 COLE Research & Design, Inc. Oral suction device
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
KR102438295B1 (ko) 2014-09-19 2022-08-31 시와 코퍼레이션 염증 및 자가 면역 질환을 치료하기 위한 노화 방지 항체
WO2016061532A1 (en) * 2014-10-16 2016-04-21 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CA3000815C (en) * 2015-10-13 2022-11-01 Siwa Corporation Anti-age antibodies and methods of use thereof
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US10981021B2 (en) 2016-03-11 2021-04-20 Carthera Method for transiently disrupting a region of the blood-brain barrier of a human
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
US10172684B2 (en) 2016-04-29 2019-01-08 Ethicon Llc Lifecycle monitoring features for surgical instrument
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
RU2617313C1 (ru) 2016-07-18 2017-04-24 Государственное автономное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Институт медицинских клеточных технологий" Способ определения биологического возраста у мужчин
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
KR20200003067A (ko) 2017-05-04 2020-01-08 시와 코퍼레이션 진단용 최종 당화 산물 항체
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020023532A1 (en) 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
WO2020036973A1 (en) 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
EP3840840A1 (en) 2018-08-23 2021-06-30 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
AU2021264007A1 (en) 2020-05-01 2022-12-08 Siwa Corporation Methods of treating infections
WO2021247397A2 (en) 2020-06-04 2021-12-09 Siwa Corporation Methods and compositions for enhancing the immune system
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2023177390A1 (en) 2022-03-14 2023-09-21 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer

Also Published As

Publication number Publication date
JP2019511469A (ja) 2019-04-25
JP6811887B2 (ja) 2021-01-13
CA3021150C (en) 2023-02-07
RU2018132998A (ru) 2020-03-19
EP4067386A1 (en) 2022-10-05
RU2018132998A3 (hu) 2020-05-29
RU2728964C2 (ru) 2020-08-03
CA3021150A1 (en) 2017-08-24
CN109071675A (zh) 2018-12-21
AU2017219749B2 (en) 2022-01-06
EP3677598A1 (en) 2020-07-08
PL3337829T3 (pl) 2020-05-18
KR20180110090A (ko) 2018-10-08
IL261006B (en) 2021-06-30
KR20230074837A (ko) 2023-05-31
US11833202B2 (en) 2023-12-05
DK3677598T3 (da) 2022-05-30
ES2912064T3 (es) 2022-05-24
IL283726A (en) 2021-07-29
EP3677598B1 (en) 2022-04-06
AU2017219749A1 (en) 2018-08-23
WO2017143073A1 (en) 2017-08-24
HK1256931A1 (zh) 2019-10-04
US20190031781A1 (en) 2019-01-31
ES2770787T3 (es) 2020-07-03
JP6722293B2 (ja) 2020-07-15
MX2022014630A (es) 2023-02-23
DK3337829T3 (da) 2020-02-17
EP3337829B1 (en) 2020-01-08
JP2020158531A (ja) 2020-10-01
EP3337829A1 (en) 2018-06-27
IL261006A (en) 2018-10-31
KR102536017B1 (ko) 2023-05-24
PT3337829T (pt) 2020-02-10
MX2018009988A (es) 2018-12-17
HUE047922T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
IL283726A (en) Method and preparation for treating cancer, killing metastatic cancer cells and preventing cancer metastases using an antibody to advanced glycation end products
PL3283435T3 (pl) Kompozycja, materiały cząsteczkowe i sposoby wytwarzania materiałów cząsteczkowych
EP3355643A4 (en) Method for processing channel collisions in direct mode operation mode, and terminal
HK1257490A1 (zh) 用於治療犬癌症的嵌合aav-抗vegf
EP3033091A4 (en) Method and compositions for treating cancer using probiotics cross-reference to related application
EP3361251A4 (en) METHOD FOR DETECTION OF CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE IN CANCER CELLS, AND COMPOSITION FOR TREATING CANCER
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
SG11201507654WA (en) Method, apparatus, and computer-readable medium for advancing prepaid credit
IL248766B (en) A method for treating renal cell cancer
SI3095722T1 (sl) Embalaža za živila, zlasti za prigrizke, ter postopek za izdelavo le-te
EP3294301A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH
PT3245032T (pt) Aparelho e método para cortar produtos
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
IL269769B (en) Mixtures, composition and their use for cancer treatment
EP3273970A4 (en) Methods and materials for treating cancer
EP3199152A4 (en) Anti-cancer agent and method for killing cancer cells
PL3307065T3 (pl) Komórki chimeryczne związane z dystrofią mięśniową i sposób leczenia dystrofii mięśniowych
ZA201507149B (en) System for treating waste water containing at least one cosmetic product, and related arrangement and method
SG11201604454QA (en) Composition, method for preparing sugar chain sample, and method for analyzing sugar chain
PT3128840T (pt) Produto fertilizante e bioestimulante contendo fruto-oligossacáridos, método de aplicação e usos
PL3518911T3 (pl) Rad1901 do zastosowania w leczeniu nowotworu jajnika
EP3522925A4 (en) METHOD FOR TREATING CANCER METASTASES AND COMPOSITION THEREOF
PT3255243T (pt) Método de extracção de materiais naturais, nomeadamente rochas